Onco-Summaries: Daily Oncology Updates at a Glance

11/07/2025

Cel-Sci to partner with a leading Saudi Arabian pharma company for Multikine in the Tx of Head & Neck Cancer (Ref)

Cel-Sci Corporation announced an agreement with one of Saudi Arabia’s premier pharmaceutical and healthcare companies for a partnership that spans regulatory and commercial activities for Multikine (Leukocyte Interleukin, Injection) in the Kingdom of Saudia Arabia

• The Saudi pharmaceutical partner which will file a Breakthrough Medicine Designation application for Multikine with the Saudi Food and Drug Authority (SFDA)

  
  

• Following the Breakthrough Medicine Designation, if granted, Multikine would immediately become available for patient access and reimbursement/sale in Saudi Arabia